Biodegradation of polysiloxanes in lymph nodes of rats measured with 29Si NMR

Biomaterials

Volumn 20, Issue 6, 1999, Pages 561-571

  Pfleiderer, Bettina ^a,b   Moore, Anna ^a   Tokareva, Elena ^a   Ackerman, Jerome L ^a   Garrido, Leoncio ^a  

^a NMR Center   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Biodegradation; Lymph nodes; Silicon 29 NMR; Silicones

Indexed keywords

BIODEGRADATION; EMULSIONS; METABOLITES; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SILICONES;

LYMPH NODES;

IMPLANTS (SURGICAL);

POLYSILOXANE; SILICON;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADATION; CONTROLLED STUDY; EMULSION; GEL; HYDROLYSIS; IMPLANT; LYMPH NODE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; BIOPOLYMERS; DIMETHYLPOLYSILOXANES; EMULSIONS; ISOTOPES; LYMPH NODES; MAGNETIC RESONANCE SPECTROSCOPY; RATS; RATS, SPRAGUE-DAWLEY; SILICON; SILICONES; SILOXANES;

EID: 0033106116     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(98)00208-7     Document Type: Article

References (42)

1. [1] Van Noort R, Black MM. Silicone rubbers for medical applications. In: Williams DF, editor. Biocompatibility of clinical implant materials. Boca Raton, FL: CRC Press, 1981:79-98.
2. [2] Cook RR, Perkins LL. The prevalence of breast implants among women in the United States. In: Potter M, Rose NR, editors. Immunology of silicones. Current topics in microbiology and immunology, vol. 210. Heidelberg: Springer, 1996:419-25.
3. [3] Kessler DA. The basis for the FDA's decision on breast implants. N Eng J Med 1992;326:1713-5.
4. [4] Picha GJ, Goldstein JA. Analysis of the soft-tissue response to components used in the manufacture of breast implants: rat animal model. Plas Reconstr Surg 1991;87:490-500.
5. [5] LeVier RR, Harrison MC, Cook RR, Lane TH. What is silicone? Plas Reconstr Surg 1993;92:163-7.
6. [6] Peters W, Smith D, Lugowski S, McHugh A, MacDonald P, Baines C. Silicon and silicone levels in patients with silicone implants. In: Potter M, Rose NR, editors. Immunology of silicones. Current topics in microbiology and immunology, vol. 210. Heidelberg: Springer, 1996:39-48.
7. [7] McGrath MH, Burkhardt BR. The safety and efficacy of breast implants for augmentation mammaplasty. Plast Reconstr Surg 1984;74:550-60.
8. [8] Yu TL, Latorre G, Marotta J, Batich C, Hardt NS. In vitro measurement of silicone bleed from breast implants. Plast Reconstr Surg 1995;97:756-64.
9. [9] Winding O, Christensen L, Thomsen JL et al. Silicone in human breast tissue surrounding silicone gel prostheses. Scand J Plast Reconstr Surg 1988;22:127-30.
10. [10] Truong LD, Cartwright J, Goodman MD, Woznicki D. Silicone lymphadenopathy associated with augmentation mammaplasty. Am J Surg Pathol 1988;12:484-91.
11. [11] Lee PL, Young VL, Garrido L. Analysis of periprosthetic capsular tissue by magic angle spinning solid-state nmr. In: 37th Experimental NMR Conference. Asilomar, CA, 17-22 March 1996.
12. [12] de Camara DL, Sheridan JM, Kammer BA. Rupture and aging of silicone gel breast implants. Plast Reconstr Surg 1993;91:828-34.
13. [13] Robinson OG, Bradley EL, Wilson DS. Analysis of explanted silicone implants: a report of 300 patients. Ann Plast Surg 1995;34:1-7.
14. [14] Cohen BE, Biggs TM, Cronin ED, Collins DR. Assessment and longevity of the silicone gel breast implant. Plast Reconstr Surg 1997;99:1597-601.
15. [15] Winding O, Christensen L, Thomsen JL et al. Silicone in human breast tissue surrounding silicone gel prostheses. Scand J Plast Reconstr Surg 1988;22:127-30.
16. [16] Greene WB, Raso DS, Walsh LG, Harley RA, Silver RM. Electron probe microanalysis of silicon and the role of the macrophage in proximal (capsule) and distant sites in augmentation mammaplasty patients. Plast Reconstr Surg 1995;95:513-9.
17. [17] Garrido L, Pfleiderer B, Papisov M, Ackerman JL. In vivo degradation of silicones. Mag Reson Med 1993;29:839-43.
18. [18] Pfleiderer B, Ackerman JL, Garrido L. Migration and biodegradation of free silicone from silicone gel-filled implants after long-term implantation. Mag Reson Med 1993;30:534-43.
19. [19] van Nunen SA, Getenby PA, Basten A. Post-mammoplasty connective tissue disease. Arthritis Rheum 1982;25:694-7.
20. [20] Weiner SR, Paulus HE. Chronic arthropapthy occurring after augmentation mammoplasty. Plast Reconstr Surg 1986;77:185-92.
21. [21] Endo LP, Edwards NL, Longley S, Corman LC, Panush RS. Silicone and rheumatic diseases. Semin Arthritis Rheum 1987;17:112-8.
22. [22] Spiera H. Scleroderma after silicone augmentation mammoplasty. JAMA 1988;260:236-8.
23. [23] Brozena SJ, Fenske NA, Cruse CW et al. Human adjuvant disease following augmentation mammoplasty. Arch Dermatol 1988;124:1383-6.
24. [24] Varga J, Shumacher HR, Jimenez SA. Systemic sclerosis after augmentation mammoplasty with silicone implants. Ann Intern Med 1989;111:377-83.
25. [25] Walsh FW, Solomon DA, Espinoza LR, Adams GD, Whitelocke HE. Human adjuvant disease. A new cause of chylous effusions. Arch Inter Med 1989;149:1194-6.
26. [26] Gutierrez FJ, Espinoza LR. Progressive systemic sclerosis complicated by severe hypertension: reversal after silicone implant removal. Am J Med 1990;89:390-2.
27. [27] Sahn EE, Garen PD, Silver RM, Maize JC. Scleroderma following augmentation mammoplasty. Arch Dermatol 1990;126:1198-202.
28. [28] Bridges AJ, COnley C, Wang G, Burns DE, Vasey FB. A clinical and immunologie evaluation of women with silicone breast implants and symptoms of rheumatic disease. Ann Inter Med 1993;118:929-36.
29. [29] McGrath MH, Burkhardt BR. The safety and efficacy of breast implants for augmentation mammaplasty. Plast Reconstr Surg 1984;74:550-60.
30. [30] Sergott TJ, Limoli JP, Baldwin CM, Laub DR. Human adjuvant disease, possible autoimmune disease after silicone implantation: a review of the literature, case studies, and speculation for the future. Plast Reconstr Surg 1986;78:104-14.
31. [31] Weisman MH, Vecchione TR, Albert D, Moore LT, Mueller MR. Connective-tissue disease following breast augmentation: a preliminary test of the human adjuvant disease hypothesis. Plast Reconstr Surg 1988;82:626-30.
32. [32] Fiala TGS, Lee WPA, May JW Jr. Augmentation mammoplasty: results of a patient survey. Ann Plast Surg 1993;30:503-9.
33. [33] Sanchéz-Guerrero J, Schur PH, Sergent JS, Liang MH. Silicone breast implants and rheumatic disease. J Arthritis Rheum 1993;37:158-68.
34. [34] Gabriel SE, O'Fallon WM, Kurland LT et al. Risk of connective-tissue diseases and other disorders after breast implantation. New Engl J Med 1994;330:1697-702.
35. [35] Hennekens CH, Lee I-M, Cook NR et al. Self-reported breast implants and connective-tissue diseases in female health professionals. JAMA 1996;275:616-21.
36. [36] Coleman B. Applications of Silicon-29 NMR spectroscopy. In: Laszlo P, editor. NMR of newly accessible nuclei, vol. 2. New York: Academic Press, 1983:197-228.
37. 29Si-NMR spectroscopic results. In: Diehl P, Fluck E, Kosfeld R, editors. Oxygen-17 and silicon-29. NMR Basic principles and progress, vol. 17. Berlin: Springer, 1981:65-235.
38. [38] Bennett DR, Gorzinski SJ, LeBeau JE. Structure-activity relationships of oral organosiloxanes on the male reproductive system. Toxicol Appl Pharmacol 1972;21:55-67.
39. [39] Hayden JF, Barlow SA. Structure-activity relationships of organosiloxanes and the female reproductive system. Toxicol Appl Pharmacol 1972;21:68-79.
40. [40] Tacke R, Linoh H. Bioorganosilicon chemistry. In: Patai S, Rappoport Z, editors. The chemistry of organic silicon compounds, ch. 18. New York: Wiley, 1989:1143-206.
41. [41] Felix K, Janz S, Pitha J et al. Cytotoxicity and membrane damage in vitro by inclusion complexes between γ-cyclodextrin and siloxanes. In: Potter M, Rose NR, editors. Immunology of silicones. Current topics in microbiology and immunology, vol. 210. Heidelberg: Springer, 1996:93-9.
42. [42] Stoseel TP. Phagocytosis (Three parts). New Engl J Med 1974;290:717-839.